Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential

Johnson & Johnson · Company update · November 16, 2026

Johnson & Johnson reached an agreement to acquire Ollin Biosciences, adding the Phase 3 investigational bispecific antibody OLN324 to its portfolio. The treatment is designed for retinal vascular diseases such as wet AMD and diabetic macular edema.

Read the announcement

AntSpace’s summary of Johnson & Johnson’s own announcement: read the original.

More updates from Johnson & Johnson